Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma
NCT00022893 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2005-06-24
Summary
The purpose of this study is to enable retreatment with Iodine-131 Anti-B1 Antibody therapy for patients with non-Hodgkin's lymphoma (NHL) who previously responded (PR, CCR, or CR) for at least 3 months to Iodine-131 Anti-B1 Antibody therapy.
Conditions
- Non-Hodgkin's Lymphoma
Interventions
- DRUG
-
Iodine-131 Anti-B1 Antibody
Sponsors & Collaborators
- collaborator INDUSTRY
-
Corixa Corporation
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
- United Kingdom
Study Locations
More Related Trials
-
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)
NCT01573000 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia
NCT00022880 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
NCT00996593 ·Status: COMPLETED ·Phase: PHASE2
-
Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
NCT00996996 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
NCT00950755 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
NCT00078598 ·Status: UNKNOWN ·Phase: PHASE3
-
Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP
NCT01868035 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
NCT00022945 ·Status: COMPLETED ·Phase: PHASE2
-
Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.
NCT01663714 ·Status: COMPLETED ·Phase: PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00004874 ·Status: TERMINATED ·Phase: PHASE3
-
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
NCT00770224 ·Status: COMPLETED ·Phase: PHASE2
-
Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies
NCT01224821 ·Status: COMPLETED ·Phase: PHASE2
-
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
NCT00107380 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
NCT00992992 ·Status: COMPLETED ·Phase: PHASE2
-
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma
NCT00989664 ·Status: COMPLETED ·Phase: PHASE2
-
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00073931 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
NCT00268983 ·Status: COMPLETED ·Phase: PHASE3
-
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
NCT00860171 ·Status: TERMINATED ·Phase: PHASE1
-
Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
NCT00416312 ·Status: COMPLETED
-
Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma
NCT00028613 ·Status: COMPLETED ·Phase: PHASE1
-
Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab
NCT00240578 ·Status: COMPLETED
-
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
NCT00319332 ·Status: WITHDRAWN ·Phase: PHASE3
-
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
NCT04526834 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab
NCT00240591 ·Status: COMPLETED
-
Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma
NCT01536561 ·Status: COMPLETED ·Phase: PHASE1